Risk of second primary cancer in patients with B-cell non-Hodgkin lymphoma receiving rituximab-containing chemotherapy: a nationwide population-based study.
This study aimed to evaluate the risk of second primary cancer (SPC) in patients receiving rituximab-containing chemotherapy. A nationwide, population-based study was conducted using the National Health Insurance Database of Taiwan. Propensity score matching was performed to correct sample selection bias and logistic regression analysis was used to calculate odds ratios. Patients receiving rituximab-containing chemotherapy or conventional chemotherapy were enrolled. After adjustment by propensity score matching, there were 1,607 patients in each group. SPC was noted in 11 patients (0.68%) with rituximab-containing chemotherapy and in 19 patients (1.18%) with conventional chemotherapy (p=0.142). There was no significant difference in the age distribution at onset of SPC (p=0.327). Multivariate logistic regression analysis revealed rituximab-containing chemotherapy was not associated with risk of SPC (odds ratio (OR)=0.58; 95% confidence interval (CI)=0.28-1.23; p=0.157). Incorporation of rituximab into conventional anti-lymphoma chemotherapy did not increase the risk of SPC in patients with B-cell non-Hodgkin lymphoma (NHL).